COMP <GO>
AUPH vs PBH // ALTMAN Z-SCORE & DEBT/EQUITY
Aurinia Pharmaceuticals Inc (NASDAQ) VS. Prestige Consumer Healthcare Inc. (NYSE) • 15-METRIC TALLY: AUPH 9
— PBH 3
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: AUPH
LAST: $17.21 (-0.86%) • MKT CAP: $2.29B
balance-sheet
8.33
LAST: $48.75 (+2.01%) • MKT CAP: $2.31B
balance-sheet
2.21
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. PBH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | PBH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 54.70% | +33.80 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 13.80% | +2.70 | AUPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | 7.0x | +14.10 | PBH | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 10.67% | -4.75 | PBH | /fcf-yield <GO> |
| Operating Margin | 37.10% | 28.40% | +8.70 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 17.50% | +50.50 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | -4.30% | +24.70 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 8.33 | 2.21 | +6.12 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | AUPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 52.5 | +4.80 | AUPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | 11.3x | -4.60 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $2.31B | -$19.7M | PBH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | PBH REV | AUPH GROSS % | PBH GROSS % | AUPH FCF | PBH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $1.09B | 88.5% | 54.7% | $135.7M | $246.4M |
| FY 2024 | $235.1M | $1.14B | 88.0% | 55.8% | $44.4M | $243.3M |
| FY 2023 | $175.5M | $1.13B | — | — | -$33.5M | $248.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
PBH // BETA —